Literature DB >> 21481786

Resisting targeted therapy: fifty ways to leave your EGFR.

Paul Workman1, Paul A Clarke.   

Abstract

Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic workarounds.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21481786     DOI： 10.1016/j.ccr.2011.03.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  14 in total

1.  Promise and challenges on the horizon of MET-targeted cancer therapeutics.

Authors:  Yu-Wen Zhang
Journal:  World J Biol Chem       Date:  2015-05-26

Review 2.  Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.

Authors:  Chien-Chung Lin; Wei-Lun Huang; Fang Wei; Wu-Chou Su; David T Wong
Journal:  Expert Rev Mol Diagn       Date:  2015-09-30       Impact factor: 5.225

3.  Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.

Authors:  Collin M Blakely; Trever G Bivona
Journal:  Cancer Discov       Date:  2012-10       Impact factor: 39.397

Review 4.  Mechanisms of resistance to EGFR targeted therapies.

Authors:  Gorjan Hrustanovic; Bianca J Lee; Trever G Bivona
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

5.  An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Authors:  Laetitia Seguin; Shumei Kato; Aleksandra Franovic; M Fernanda Camargo; Jacqueline Lesperance; Kathryn C Elliott; Mayra Yebra; Ainhoa Mielgo; Andrew M Lowy; Hatim Husain; Tina Cascone; Lixia Diao; Jing Wang; Ignacio I Wistuba; John V Heymach; Scott M Lippman; Jay S Desgrosellier; Sudarshan Anand; Sara M Weis; David A Cheresh
Journal:  Nat Cell Biol       Date:  2014-04-20       Impact factor: 28.824

Review 6.  Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment.

Authors:  Anne Poder Andersen; José M A Moreira; Stine Falsig Pedersen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-02-03       Impact factor: 6.237

7.  Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Authors:  Luping Lin; Trever G Bivona
Journal:  Chemother Res Pract       Date:  2012-08-29

8.  Return of the malingering mutants.

Authors:  M Greaves
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

Review 9.  Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

Authors:  D Gonzalez de Castro; P A Clarke; B Al-Lazikani; P Workman
Journal:  Clin Pharmacol Ther       Date:  2012-12-07       Impact factor: 6.875

10.  Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Authors:  M Beloueche-Babari; Y Jamin; V Arunan; S Walker-Samuel; M Revill; P D Smith; J Halliday; J C Waterton; H Barjat; P Workman; M O Leach; S P Robinson
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.